Articles related to ENDOMETRIAL CANCER

ACOG has revised its approach to postmenopausal bleeding evaluation, recommending combined transvaginal ultrasonography and endometrial sampling for most patients at initial presentation. The update reflects rising endometrial cancer incidence, evolving evidence on cancer subtypes, and recognized limitations of ultrasound-only evaluation.

PCOS was associated with significantly elevated risk for breast, uterine, ovarian/fallopian tube, and cervical cancers in a matched cohort of more than 2.5 million women.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.

A jury assigned 35% of liability to a second-opinion physician and health center after a patient underwent an unnecessary hysterectomy based on a contaminated biopsy specimen, finding that discordant pathology results were not reconciled and informed consent was not obtained.

Vaginal fluid collection via tampon under clinical supervision followed by bisulfite conversion and long-probe quantitative amplified signal assays for methylated DNA marker analysis.